• We are available for your help 24/7
  • Email: info@isindexing.com, submission@isindexing.com


Paper Details

PHARMACEUTICAL EVALUATION OF DIFFERENT SUPER DISINTEGRANTS IN DESIGN OF METOPROLOL TARTRATE ORODISPERSIBLE TABLETS

Uday Bhasker GoudGoundla*, Jakkampudi Sri Venu Prakash, Pranav KumarAvadhanam, Sreenivas ReddyGangi Reddy, ManikantaSai Krashna, PangaJanaki Ramulu

Journal Title:World Journal of Pharmaceutical Research
Abstract


Purpose: The Purpose of the present study was to develop orodispersible tablets of metoprolol tartrate (beta blocker used in treatment of angina pectoris, hypertensionand congestive heart failure.) for improving patient compliance, especially, those of paediatric and geriatric categories facing problem or difficulties in swallowing. Orodispersible tablets of metoprolol tartrate Prepared with different super disintegrates by using direct compression method. Methods: Orally disintegrating tablets of metoprolol tartrate was prepared using three different super disintegrates namely croscaramellose sodium, crospovidone and sodium starch glycolate with three concentrations (3%, 6% and 9%) were prepared by direct compression method. The final blend of the drug and excipients were evaluated for powder flow properties, bulk density, tapped density and compressibility index. All the formulations were evaluated for weight variation, thickness, disintegration time, hardness, friability, wetting time and water absorption ratio. Results: The optimised formulation F4 containing 3% w/w crospovidone, showing maximum drug release within 10min. Short-term stability studies (at 402o/755% relative humidity) on the best formulation indicated that there are no significant changes in drug content and in vitro disintegration time. FTIR-spectroscopic studies indicated that there are no drugexcipients interactions. Conclusions: The present study clearly demonstrates that orodispersible tablets of metoprololtartrate could be successfully prepared by direct compression method and It can be concluded that the tablets containing 3% crospovidone F4 formulation is optimized due to its fast in-vitro dispersion when compare to other formulation.

Download